MiNK Therapeutics, Inc.
MiNK Therapeutics develops allogeneic, ex-vivo expanded invariant natural killer T cell therapies for cancer and immune-mediated diseases. Its lead candidate, agenT-797, is an off-the-shelf native iNKT cell therapy in clinical development for solid tumors, severe pulmonary conditions and graft-versus-host disease. The company is also developing engineered candidates, including MiNK-413, a BCMA-targeting CAR-iNKT therapy, and MiNK-215, a FAP-targeting CAR-iNKT therapy, as well as TCR-based therapies and iNKT cell engagers. Its proprietary personalized neoantigen library supports development of patient-specific TCR therapies. MiNK makes its product candidates using in-house, closed-system manufacturing capabilities and pursues development independently and through collaborations, including access to immuno-oncology antibodies and adjuvants from Agenus. The company is headquartered in New York, NY, and conducts manufacturing for its native iNKT cell programs in Lexington, Massachusetts.
H.C. Wainwright initiated coverage on MiNK Therapeutics (INKT) with a buy rating and $38 price target, citing potential upside from $10.79. The biotech firm reported a narrowed Q2 2026 net loss of $3.1M, better than estimates. Its lead asset, agenT-797, is in Phase 2b/3 trials for ARDS, with interim data expected in late 2027.
MiNK Therapeutics (INKT) will present data at SITC 2026 on agenT-797 for treatment-resistant colorectal cancer and MiNK-215 for eliminating senescent tumor cells. Preclinical studies support ongoing Phase 2 trials for colorectal cancer liver metastases.
MiNK Therapeutics (INKT) was selected for ARPA-H's BoSS program, which aims to develop room-temperature storage for cell therapies. The company will receive funding as part of a team led by Draper Lab, focusing on its agenT-797 iNKT platform. ARPA-H committed up to $87 million for the four-year program, aiming to reduce cold-chain dependence and expand access to cell-based medicines.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning INKT (MiNK Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent INKT coverage spans financial news, earnings and corporate actions.
In the last 30 days, INKT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($73K). The most active reporter was Buell Jennifer, Chief Executive Officer, with 1 filing.
Analyst initiation suggests significant upside potential.
Preclinical data may improve sentiment but the therapies are still early-stage.
Selection validates the platform and may boost investor confidence.
The filing adds fresh clinical validation signals (randomized Day 28 alive/afebrile, improved oxygenation, no major SAEs attributed) and incremental business traction (paid international access infrastructure).
Routine shareholder-meeting vote disclosure; no new operating, financial, or regulatory catalyst beyond governance outcomes.
AlphAI scores every news story that mentions INKT with an AI model for sentiment and relevance, and aggregates insider trades from MiNK Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright initiated coverage on MiNK Therapeutics (INKT) with a buy rating and $38 price target, citing potential upside from $10.79. The biotech firm reported a narrowed Q2 2026 net loss of $3.1M, better than estimates. Its lead asset, agenT-797, is in Phase 2b/3 trials for ARDS, with interim data expected in late 2027.
2 min readMiNK Therapeutics (INKT) will present data at SITC 2026 on agenT-797 for treatment-resistant colorectal cancer and MiNK-215 for eliminating senescent tumor cells. Preclinical studies support ongoing Phase 2 trials for colorectal cancer liver metastases.
1 min readMiNK Therapeutics (INKT) was selected for ARPA-H's BoSS program, which aims to develop room-temperature storage for cell therapies. The company will receive funding as part of a team led by Draper Lab, focusing on its agenT-797 iNKT platform. ARPA-H committed up to $87 million for the four-year program, aiming to reduce cold-chain dependence and expand access to cell-based medicines.
2 min readMiNK Therapeutics, Inc. (INKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury • First patients treated in randomized Phase 2 trial C-1300-02 were alive at Day 28, with improved oxygenation, infection contr
6 min readMiNK Therapeutics, Inc. (INKT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001840229 false 0001840229 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min readSciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.
6 min readThis document is an earnings call summary for MiNK Therapeutics (INKT.US) for their Q1 2026 financial results. It provides an overview of the key financial and operational highlights discussed during the conference call.
2 min readMiNK Therapeutics reported its Q4 and full-year 2025 financial results, highlighting a cash balance of $13.4 million and advancing its Phase 2 ARDS and GVHD programs. The company plans to initiate its Phase 2 ARDS trial in the first half of 2026, targeting 200,000-300,000 patients annually in the US and EU, with clinical readouts expected in the second half of 2026. MiNK is also benefiting from non-dilutive funding, including a $1.1 million collaboration with C-Further and grants for its GVHD program.
3 min readMiNK Therapeutics will initiate a Phase 1 clinical trial for its lead therapy, agenT-797, to evaluate its potential in reducing graft-versus-host disease (GvHD) and other complications in patients with high-risk leukemias and blood cancers. The therapy is an off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy that has previously shown safety and immune-modulating activity. This trial marks the company's expansion into transplantation medicine, aiming to suppress inflammatory immune responses while preserving anti-leukemia activity.
2 min readNEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- MiNK Therapeutics, Inc. ( NASDAQ: INKT ) , a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T ( iNKT ) cell therapies to treat cancer and immune disorders, today announced the publication of new preclinical ...
4 min read
